Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Most pharmaceuticals sold today have their origin in a biochemistry laboratory. Drug discovery has traditionally started with a biochemical pathway implicated in a pathophysiological process. An ...

Long before a liver tumor appears, a high-fat diet can push liver cells into a risky survival mode. That is the central ...

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...

The global metagenomics sequencing market size was US$ 1139.3 million in 2021. The global metagenomics sequencing market is forecast to grow to US$ 3,994.01 million by 2030 by registering a compound ...

The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.

Pipettes? Check. Centrifuges? Check. Microplates? Check. Gloves? Check. Salmon sperm DNA? Check. Wait what? There are a ...

Abstract: Conventional microarray-based biosensors can only detect a limited number of organisms, and adding sensor capabilities requires re-engineering of reagents and devices to detect the presence ...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

According to Precedence Research, the global microarray market size was estimated at USD 5.46 billion in 2023 and is projected to reach USD 13.81 billion by 2034, registering a CAGR of 8.8% from 2024 ...